172 related articles for article (PubMed ID: 27256404)
1. Effect of (18)F-fluorodeoxyglucose extravasation on time taken for tumoral uptake to reach a plateau: animal and clinical PET analyses.
Lee JJ; Chung JH; Kim SY
Ann Nucl Med; 2016 Oct; 30(8):525-33. PubMed ID: 27256404
[TBL] [Abstract][Full Text] [Related]
2. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
3. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
[TBL] [Abstract][Full Text] [Related]
4. Comparison of image quality between step-and-shoot and continuous bed motion techniques in whole-body
Yamashita S; Yamamoto H; Nakaichi T; Yoneyama T; Yokoyama K
Ann Nucl Med; 2017 Nov; 31(9):686-695. PubMed ID: 28815414
[TBL] [Abstract][Full Text] [Related]
5. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT.
Büsing KA; Schönberg SO; Brade J; Wasser K
Nucl Med Biol; 2013 Feb; 40(2):206-13. PubMed ID: 23228852
[TBL] [Abstract][Full Text] [Related]
6. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
7. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging.
Toriihara A; Yoshida K; Umehara I; Shibuya H
Ann Nucl Med; 2011 Apr; 25(3):173-8. PubMed ID: 21088936
[TBL] [Abstract][Full Text] [Related]
8. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
[TBL] [Abstract][Full Text] [Related]
9. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
11. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
12. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
14. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
15. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
16. Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging.
Williams JM; Arlinghaus LR; Rani SD; Shone MD; Abramson VG; Pendyala P; Chakravarthy AB; Gorge WJ; Knowland JG; Lattanze RK; Perrin SR; Scarantino CW; Townsend DW; Abramson RG; Yankeelov TE
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2374-2380. PubMed ID: 27557845
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Static and Dynamic
Braune A; Hofheinz F; Bluth T; Kiss T; Wittenstein J; Scharffenberg M; Kotzerke J; Gama de Abreu M
J Nucl Med; 2019 Nov; 60(11):1629-1634. PubMed ID: 31053684
[TBL] [Abstract][Full Text] [Related]
18. Optimizing 18F-FDG Uptake Time Before Imaging Improves the Accuracy of PET/CT in Liver Lesions.
Al-Faham Z; Jolepalem P; Rydberg J; Wong CY
J Nucl Med Technol; 2016 Jun; 44(2):70-2. PubMed ID: 26966128
[TBL] [Abstract][Full Text] [Related]
19. Pictorial review of
Ishibashi M; Tanabe Y; Fujii S; Ogawa T
Ann Nucl Med; 2017 Jul; 31(6):437-453. PubMed ID: 28585058
[TBL] [Abstract][Full Text] [Related]
20. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
